FDA has approved an expanded indication for AstraZeneca’s Farxiga (dapagliflozin). This decision, marking a significant milestone in Farxiga’s development, opens up its use in patients with heart failure, regardless of their ejection fraction status. This brings the total number of Farxiga’s approved indications to five. Ejection fraction in heart failure Ejection fraction is a key measure…

Novartis’ Entresto could lead the charge on an impressive uptick in growth for the heart failure treatment space, according to a new analysis from research and consulting firm GlobalData. The report predicts the market value for these treatments will go from $3.7 billion in 2016 to an estimated $16.1 billion by 2026 signifying an increase…